A Phase 2 interventional study of Placebo and PF-06823859 in Lupus Erythematosus, Systemic and Lupus Erythematosus, Cutaneous, sponsored by Pfizer. Terminated at 19 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 365th largest by enrollment of the 407 interventional ones that give a count, is one of 23 that started in 2023, is one of 120 in phase 2, and was the 379th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Fate Therapeutics · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
477 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 130 · Phase 2 151 · Phase 3 75 · Phase 4 17
First in 1986; this study’s year is marked. 23 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 70 across the 407 interventional studies, 223 across the 67 observational. Of the 309 that completed or were terminated, 147 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
264 of 477 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
33 of the studies in Lupus Erythematosus, Systemic with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05639114Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | 2027-03-26 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms.
This study is seeking for participants who:
About 48 participants will be selected to receive active study medicine (PF-06823859) or placebo (an infusion without drug). About 32 are grouped to receive the active study medicine and 16 are to receive placebo. They will be receiving the treatments by intravenous infusion (injected directly into the veins).
At week 16 all participants receiving the active study drug since day 1 and participants who have received placebo since day 1 and are not responding clinically will receive active study medication. Patients who have received placebo since Day 1 and who have had a clinical response will continue to receive placebo till week 40. All participants will have last follow-up visit at Week 60.
The study will compare participants receiving PF-06823859 to participants who receive placebo. This will help us see if PF-06823859 is safe and effective to treat CLE or SLE with skin symptoms and improve participant's CLASI-A score. Participants will take part in this study for about 65 weeks. This includes up to a 5-week selection period, a 12-week Q4Wk treatment period, a 36-week Q8Wk treatment period, and a 12-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-06823859
Drug: PF-06823859
Placebo
Drug: Placebo
Placebo (intravenous infusion)
PF-06823859 (intravenous infusion)
Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12
Change from baseline GS was calculated as GS(t) - GS(0), where GS(t) was the gene signature score at Week 12 and GS(0) was the gene signature score at Baseline, where the GS(t) was calculated as the mean of log2 transformed counts per million reads from each of 13 genes in RNAseq, the higher GS indicated coordinated higher expression. There is no minimum/maximum limit to the GS score. Gene expression was quantified using RNA sequencing and summarized as log2-transformed counts per million mapped reads \[log2(CPM)\]. Higher values indicate higher normalized gene expression and without a bounded scale or defined minimum or maximum value.
Time frame: Baseline, Week 12
Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) Score at Week 12
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease.
Time frame: Baseline, Week 12
Percent Change From Baseline in CLASI-A Score at Weeks 4, 8, 16, 20, 24, 32, 40, 48 and 60
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
Time frame: Baseline, Weeks 4, 8, 16, 20, 24, 32, 40, 48 and 60
Change From Baseline in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Percentage of Participants With Greater Than or Equal to (>=) 50 Percent Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=50 percent reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Percentage of Participants With >=4 Points Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=4 points reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Percentage of Participants With >=7 Points Reduction in CLASI-A Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=7 points reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Change From Baseline in Physician Global Assessment (PhGA) Score at Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
PhGA score was assigned by physician as the number within the 0 to 100 millimeter range on visual assessment scale and provided a global characterization of disease. Higher scores indicating more severe disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 32, 40, 48 and 60
Number of Participants With Laboratory Test Abnormalities of Grade 3 or More According to Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0
Laboratory test included activated partial thromboplastin time prolonged, alanine aminotransferase increased, alkaline phosphatase increased, anemia, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase (CPK) increased, cholesterol high, creatinine increased, hemoglobin increased, hypercalcemia, hyperkalemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, international normalized ratio (INR) increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell decreased. Laboratory test abnormalities were graded according to CTCAE v5.0; grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Participants with any laboratory abnormalities of CTCAE v5.0 grade 3 or more were reported in this outcome measure.
Time frame: For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60
Number of Participants With Clinically Significant Vital Signs Abnormalities
Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). Clinically significant vital signs abnormalities were based on investigator's decision.
Time frame: For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60
Number of Participants With Clinically Significant Electrocardiogram (ECG) Results
ECG parameters included PR interval, QRS duration and QT interval using Fridericia's formula (QTcF) interval. Clinically significant abnormalities in ECG parameters were based on investigator's decision.
Time frame: For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Who Discontinued Study Due to TEAEs
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were the AEs with onset dates on or after the start of the study intervention up to after last dose of study intervention. An serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other pre-specified criteria in protocol of the study or other important medical events. AEs included SAEs (if occurred) and all other AEs (including non-SAEs).
Time frame: For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60
Initially participants were randomized to receive PF-06823859 or placebo in Period 1. In Period 2, participants in PF-06823859 group continued to receive the same, while participants who received placebo, depending upon the response, either continued receiving placebo (if responded to treatment) or were administered with PF-06823859 (non-responders). No participants continued to receive placebo in Period 2.
| Milestone | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Started | 6 | 2 |
| Completed | 6 | 2 |
| Not completed | 0 | 0 |
| Milestone | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Started | 6 | 2 |
| Completed | 3 | 1 |
| Not completed | 3 | 1 |
| Withdrew: Study terminated by sponsor | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Milestone | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Started | 6 | 2 |
| Completed | 5 | 1 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
Change from baseline GS was calculated as GS(t) - GS(0), where GS(t) was the gene signature score at Week 12 and GS(0) was the gene signature score at Baseline, where the GS(t) was calculated as the mean of log2 transformed counts per million reads from each of 13 genes in RNAseq, the higher GS indicated coordinated higher expression. There is no minimum/maximum limit to the GS score. Gene expression was quantified using RNA sequencing and summarized as log2-transformed counts per million mapped reads \[log2(CPM)\]. Higher values indicate higher normalized gene expression and without a bounded scale or defined minimum or maximum value.
| log2(CPM) units | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Change From Baseline in Type 1 Interferon (IFN) Gene Signature (GS) Score in Lesional Skin at Week 12 | -1.1 (-3.0 to 0.8) | -1.6 (-4.9 to 1.8) |
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease.
| Percent change | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) Score at Week 12 | -35.6 ± 21.28 | -8.2 ± 5.41 |
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
| Percent change | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Week 4 | -7.7 ± 32.09 | -44.3 ± 50.42 |
| Week 8 | -22.8 ± 23.14 | -12.3 ± 5.16 |
| Week 16 | -27.9 ± 41.0 | 11.7 ± 28.78 |
| Week 20 | -29.8 ± 33.23 | -28.7 ± 15.99 |
| Week 24 | -23.9 ± 39.72 | -22.2 ± 25.21 |
| Week 32 | -22.8 ± 37.41 | -40.2 ± 50.67 |
| Week 40 | -7.6 ± 34.49 | -64.0 |
| Week 48 | -5.4 ± 34.93 | -68.0 |
| Week 60 | -24.2 ± 39.22 | — |
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
| Score on a scale | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Week 4 | -1.8 ± 5.04 | -11.0 ± 12.73 |
| Week 8 | -4.5 ± 4.28 | -3.0 ± 1.41 |
| Week 12 | -7.0 ± 5.66 | -2.0 ± 1.41 |
| Week 16 | -6.5 ± 8.12 | 3.0 ± 7.07 |
| Week 20 | -5.8 ± 6.49 | -7.0 ± 4.24 |
| Week 24 | -5.8 ± 8.54 | -5.5 ± 6.36 |
| Week 32 | -4.8 ± 5.89 | -10.0 ± 12.73 |
| Week 40 | -3.3 ± 7.27 | -16.0 |
| Week 48 | -2.0 ± 6.98 | -17.0 |
| Week 60 | -7.3 ± 9.02 | — |
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=50 percent reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
| Percentage of Participants | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Week 4 | 16.7 (0.9 to 58.2) | 50.0 (2.5 to 97.5) |
| Week 8 | 16.7 (0.9 to 58.2) | 0 (0.0 to 77.6) |
| Week 12 | 33.3 (6.3 to 72.9) | 0 (0.0 to 77.6) |
| Week 16 | 33.3 (6.3 to 72.9) | 0 (0.0 to 77.6) |
| Week 20 | 33.3 (6.3 to 72.9) | 0 (0.0 to 77.6) |
| Week 24 | 33.3 (6.3 to 72.9) | 0 (0.0 to 77.6) |
| Week 32 | 20.0 (1.0 to 65.7) | 50.0 (2.5 to 97.5) |
| Week 40 | 25.0 (1.3 to 75.1) | 100.0 (5.0 to 100.0) |
| Week 48 | 0 (0.0 to 52.7) | 100.0 (5.0 to 100.0) |
| Week 60 | 33.3 (1.7 to 86.5) | — |
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=4 points reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
| Percentage of Participants | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Week 4 | 33.3 (6.3 to 72.9) | 50.0 (2.5 to 97.5) |
| Week 8 | 66.7 (27.1 to 93.7) | 50.0 (2.5 to 97.5) |
| Week 12 | 66.7 (27.1 to 93.7) | 0 (0.0 to 77.6) |
| Week 16 | 50.0 (15.3 to 84.7) | 0 (0.0 to 77.6) |
| Week 20 | 66.7 (27.1 to 93.7) | 100.0 (22.4 to 100.0) |
| Week 24 | 50.0 (15.3 to 84.7) | 50.0 (2.5 to 97.5) |
| Week 32 | 60.0 (18.9 to 92.4) | 50.0 (2.5 to 97.5) |
| Week 40 | 50.0 (9.8 to 90.2) | 100.0 (5.0 to 100.0) |
| Week 48 | 25.0 (1.3 to 75.1) | 100.0 (5.0 to 100.0) |
| Week 60 | 66.7 (13.5 to 98.3) | — |
CLASI-A measures erythema and scaling or hypertrophy in thirteen skin regions. CLASI-A scores ranges from 0 to 70, with higher scores indicating more severe skin disease. Percentage of participants with \>=7 points reduction in CLASI-A score at the specified timepoints was reported in this outcome measure. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
| Percentage of Participants | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Week 4 | 16.7 (0.9 to 58.2) | 50.0 (2.5 to 97.5) |
| Week 8 | 33.3 (6.3 to 72.9) | 0 (0.0 to 77.6) |
| Week 12 | 50.0 (15.3 to 84.7) | 0 (0.0 to 77.6) |
| Week 16 | 50.0 (15.3 to 84.7) | 0 (0.0 to 77.6) |
| Week 20 | 50.0 (15.3 to 84.7) | 50.0 (2.5 to 97.5) |
| Week 24 | 50.0 (15.3 to 84.7) | 50.0 (2.5 to 97.5) |
| Week 32 | 60.0 (18.9 to 92.4) | 50.0 (2.5 to 97.5) |
| Week 40 | 25.0 (1.3 to 75.1) | 100.0 (5.0 to 100.0) |
| Week 48 | 25.0 (1.3 to 75.1) | 100.0 (5.0 to 100.0) |
| Week 60 | 66.7 (13.5 to 98.3) | — |
PhGA score was assigned by physician as the number within the 0 to 100 millimeter range on visual assessment scale and provided a global characterization of disease. Higher scores indicating more severe disease. Participants receiving PF-06823859 continued Q4W then Q8W treatment, while both participants receiving placebo switched to PF-06823859 at Week 16. Results are reported by treatment sequence to reflect protocol pathways and maintained the initial randomized comparison.
| Millimetre | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W |
|---|---|---|
| Week 4 | -11.7 ± 23.07 | -5.5 ± 7.78 |
| Week 8 | -18.5 ± 12.77 | -7.0 ± 9.9 |
| Week 12 | -25.0 ± 23.19 | 13.0 ± 19.8 |
| Week 16 | -19.8 ± 28.52 | 20.5 ± 27.58 |
| Week 20 | -26.7 ± 26.82 | 22.0 ± 31.11 |
| Week 24 | -24.7 ± 30.74 | 16.0 ± 24.04 |
| Week 32 | -24.8 ± 35.17 | 5.5 ± 21.92 |
| Week 40 | -25.3 ± 34.44 | 4.0 |
| Week 48 | -21.0 ± 35.36 | -26.0 |
| Week 60 | -37.7 ± 33.61 | 30.0 |
Laboratory test included activated partial thromboplastin time prolonged, alanine aminotransferase increased, alkaline phosphatase increased, anemia, aspartate aminotransferase increased, blood bilirubin increased, creatine phosphokinase (CPK) increased, cholesterol high, creatinine increased, hemoglobin increased, hypercalcemia, hyperkalemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia, international normalized ratio (INR) increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell decreased. Laboratory test abnormalities were graded according to CTCAE v5.0; grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Participants with any laboratory abnormalities of CTCAE v5.0 grade 3 or more were reported in this outcome measure.
| Participants | PF-06823859 (at Q4W) | PF-06823859 (at Q4W) Then PF-06823859 (at Q8W) | Placebo (at Q4W) | Placebo (at Q4W) Then PF-06823859 (at Q8W) |
|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities of Grade 3 or More According to Common Terminology Criteria for Adverse Events (CTCAE) Version (v) 5.0 | 0 | 1 | 0 | 0 |
Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR). Clinically significant vital signs abnormalities were based on investigator's decision.
| Participants | PF-06823859 (at Q4W) | PF-06823859 (at Q4W) Then PF-06823859 (at Q8W) | Placebo (at Q4W) | Placebo (at Q4W) Then PF-06823859 (at Q8W) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Vital Signs Abnormalities | 0 | 0 | 0 | 0 |
ECG parameters included PR interval, QRS duration and QT interval using Fridericia's formula (QTcF) interval. Clinically significant abnormalities in ECG parameters were based on investigator's decision.
| Participants | PF-06823859 (at Q4W) | PF-06823859 (at Q4W) Then PF-06823859 (at Q8W) | Placebo (at Q4W) | Placebo (at Q4W) Then PF-06823859 (at Q8W) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Results | 0 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were the AEs with onset dates on or after the start of the study intervention up to after last dose of study intervention. An serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other pre-specified criteria in protocol of the study or other important medical events. AEs included SAEs (if occurred) and all other AEs (including non-SAEs).
| Participants | PF-06823859 (at Q4W) | PF-06823859 (at Q4W) Then PF-06823859 (at Q8W) | Placebo (at Q4W) | Placebo (at Q4W) Then PF-06823859 (at Q8W) |
|---|---|---|---|---|
| TEAEs | 4 | 4 | 1 | 1 |
| TESAEs | 0 | 0 | 0 | 0 |
| Discontinued study due to TEAEs | 0 | 0 | 0 | 0 |
Collected over For Q4W arms: Day 1 up to pre-dose of Week 16; for Q8W arms: from dosing of Week 16 to Week 60. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06823859 (at Q4W) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| PF-06823859 (at Q4W) Then PF-06823859 (at Q8W) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Placebo (at Q4W) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Placebo (at Q4W) Then PF-06823859 (at Q8W) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Event | PF-06823859 (at Q4W) | PF-06823859 (at Q4W) Then PF-06823859 (at Q8W) | Placebo (at Q4W) | Placebo (at Q4W) Then PF-06823859 (at Q8W) |
|---|---|---|---|---|
| Lacrimation increasedEye disorders | 0/6 | 0/6 | 1/2 | 0/2 |
| COVID-19Infections and infestations | 0/6 | 1/6 | 0/2 | 1/2 |
| Eye infectionInfections and infestations | 0/6 | 0/6 | 1/2 | 0/2 |
| Iron deficiencyMetabolism and nutrition disorders | 0/6 | 0/6 | 0/2 | 1/2 |
| Disturbance in attentionNervous system disorders | 0/6 | 0/6 | 1/2 | 0/2 |
| ErythemaSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/2 | 1/2 |
| Skin lesionSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/2 | 1/2 |
| Dry eyeEye disorders | 0/6 | 1/6 | 0/2 | 0/2 |
| Vision blurredEye disorders | 1/6 | 0/6 | 0/2 | 0/2 |
| Angular cheilitisGastrointestinal disorders | 1/6 | 1/6 | 0/2 | 0/2 |
| Age, Continuous(Years) | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W | Total |
|---|---|---|---|
| Mean | 49.83 ± 7.25 | 48.0 ± 15.56 | 49.38 ± 8.53 |
| Sex: Female, Male(Participants) | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W | Total |
|---|---|---|---|
| Female | 4 | 1 | 5 |
| Male | 2 | 1 | 3 |
| Ethnicity (NIH/OMB)(Participants) | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 4 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PF-06823859 Q4W Then PF-06823859 Q8W | Placebo Q4W Then PF-06823859 Q8W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 5 | 2 | 7 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2023 to primary completion in Jun 2025, 22 months.
Results were first posted in Aug 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dazukibart
Lupus Erythematosus, Systemic →